T3 Pharma developed an efficient protein delivery technology that is based on the use of genetically modified live bacteria expressing the type 3 secretion system. While this technology can be applied widely in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach in the treatment of solid tumors.
The major challenge in cancer therapy is developing targeted treatments that exclusively impact the cancer. T3 Pharma’s bacteria have the capacity to specifically find and colonize solid tumors where the bacteria serve as efficient factories for therapeutically effective proteins.
“I stumbled upon a research discovery and wanted to bring it to its full potential.“ – Simon Ittig
Experiments on mice have shown that after a few days the modified bacteria are no longer present in the healthy tissue, but can be found in the tumor in their millions. They thrive in the cancerous tissue because the immune system in the area of a tumor is often suppressed. Preclinical studies in a number of tumor models demonstrated a substantial impact on tumor progression as well as a durable immune-mediated memory to fight recurring tumors. A first clinical trial on human patients is anticipated for the first half of 2020.
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel.